CFDA Approves BioChain's Colorectal Cancer Diagnostic Test

BioChain, a US-China diagnostics company, announced CFDA approval of Epi proColon®, a non-invasive blood-based diagnostic test for colorectal cancer. BioChain in-licensed China rights to Epi proColon from Epigenomics AG, a German-US company, in October 2013. The test was approved in only 14 months from the time of licensing, even though the process included a China clinical validation study. More details.... Stock Symbols: (F: ECX; OTCQX: EPGNY) Share this with colleagues: // //